Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Centessa Pharmaceuticals PLC (NASDAQ:CNTA), a biotech company with a market capitalization of $1.69 billion, saw its Chief Executive Officer Saurabh Saha sell 55,000 ordinary shares of the company on June 20, 2025, for a total of $694,826. The sales were executed at a weighted average price of $12.6332, with individual sales prices ranging from $12.50 to $12.80. According to InvestingPro, analysts maintain a strong buy consensus with price targets ranging from $26 to $38.
On the same day, Saha also exercised options to acquire 55,000 ordinary shares at a price of $3.85 per share, for a total value of $211,750.
Following these transactions, Saha directly owns 221,017 ordinary shares and indirectly owns 38,000 shares through a trust.
In other recent news, Centessa Pharmaceuticals has announced the appointment of Raphael Deferiere as its new Chief Accounting Officer, effective May 27, 2025. Deferiere, who previously served as an Assurance Partner at Ernst & Young, will also act as the principal accounting officer. Meanwhile, Piper Sandler has maintained its Overweight rating on Centessa Pharmaceuticals, setting a price target of $38.00. This rating reflects confidence in the company’s development of orexin receptor 2 (OX2R) agonists, including its lead candidate, ORX750, which targets narcolepsy and idiopathic hypersomnia.
BMO Capital Markets also reiterated its Outperform rating on Centessa, with a $35.00 price target, citing the potential of ORX750 and its promising Phase II results expected in 2025. The firm expressed an 80% probability of success for the drug’s trials, highlighting its ability to improve wakefulness test durations. Centessa’s broader pipeline includes other orexin agonists that could expand its market reach, though these opportunities are not yet reflected in the current stock price. Investors are closely watching the upcoming data readouts, which could validate the optimistic outlook from analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.